BEAM vs LIME: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BEAM and LIME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BEAM and LIME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both strands of the double helix, aiming for more precise fixes than first-generation CRISPR. Its pipeline spans risto-cel (formerly BEAM-101) for sickle cell disease, with a biologics license application targeted as early as year-end 2026, plus BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 and BEAM-304 for rare liver-mediated genetic diseases. The company also runs collaborations with partners including Pfizer and Eli Lilly, which supply most of its reported revenue through upfront payments and milestones.

Full BEAM guide

Lime, legally Neutron Holdings, Inc., rents electric scooters and e-bikes by the minute through its own app and through partner apps including Uber. Riders unlock a vehicle parked on a city street, take a short trip (typically a mile or two), and end the ride in a permitted area. Lime operates in roughly 230 cities across 29 countries, served about 19 million riders in 2025, and holds around 27% share of docked and dockless shared micromobility worldwide. Revenue is essentially the sum of many small rides, so the economics come down to how many vehicles are on the street, how often each one is ridden, and what it costs to charge, repair, and rebalance them. Lime discloses revenue per vehicle per day (about $8.20 in the second quarter of 2026) as its core unit measure, and the average operational fleet reached roughly 408,000 vehicles, up 22% year over year.

Full LIME guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BEAM drivers: Risto-cel sickle cell path to filing; In vivo liver franchise.
• LIME drivers: The competitive field thinned out before Lime listed; Unit economics improved faster than the fleet grew.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. For LIME, seasonality is the number the guidance turns on.

Pick BEAM if you believe its drivers more; LIME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BEAM and LIME guides.

BEAM. Beam's revenue is collaboration and milestone income, not product sales, so it is lumpy and not comparable to a profitable company's top line. With no approved therapy and heavy R&D spending, the company runs large net losses funded by its cash pile. Valuation therefore reflects the market's probability-weighted view of the pipeline rather than current earnings.

LIME. The headline trailing PE near 5x is misleading, because roughly $298 million of the ~$210 million trailing net income comes from a single non-cash tax benefit (the release of a deferred tax valuation allowance) rather than operations. The multiples that describe the business are about 2.4x trailing sales and, netting out cash, roughly 7.5x the midpoint of 2026 adjusted EBITDA guidance. Whether that is cheap depends on how much of adjusted EBITDA survives the depreciation of a fleet that has to be replaced on a multi-year cycle, and on the ~$180 million of annual capex it takes to keep that fleet on the street.

Headline figures (approximate, MAY 2026): BEAM shows market cap ~$3.6B, revenue (q1 2026) ~$31.7M, revenue (q1 2025) ~$7.5M, net loss (q1 2026) ~$94.3M; LIME shows revenue (ttm) ~$986M, q2 2026 revenue ~$304M, up ~24% year over year, q2 2026 adjusted ebitda ~$84M (~28% margin); GAAP operating profit ~$13M, market cap ~$2.41B (~2.4x trailing sales).

BEAM and LIME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BEAM and LIME exposure against your real portfolio. It is not an investment adviser.